Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes (Q42931501)

11 November 2017

Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes (English)

1 reference

11 November 2017

1 reference

coronary artery disease

1 reference

Faouzi Addad

1

1 reference

11 November 2017

Tahar Chakroun

2

1 reference

11 November 2017

Ismail Elalamy

3

1 reference

11 November 2017

Fatma Abderazek

4

1 reference

11 November 2017

Saoussen Chouchene

5

1 reference

11 November 2017

Zohra Dridi

6

1 reference

11 November 2017

Gregoris T Gerotziafas

7

1 reference

11 November 2017

Mohamed Hatmi

8

1 reference

11 November 2017

Mohsen Hassine

9

1 reference

11 November 2017

Habib Gamra

10

1 reference

11 November 2017

20 August 2010

1 reference

International Journal of Hematology

11 November 2017

1 reference

11 November 2017

92

1 reference

11 November 2017

2

1 reference

11 November 2017

296-301

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-010-0652-3

11 November 2017

0 references

cites work

Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0652-3

Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0652-3

PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients

21 January 2018

1 reference

12 December 2020

Standards of medical care in diabetes--2007.

1 reference

12 December 2020

Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar

1 reference

12 December 2020

Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin

1 reference

12 December 2020

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

1 reference

12 December 2020

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

12 December 2020

Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease

1 reference

12 December 2020

Trial of repeated low-dose aspirin in diabetic angiopathy

1 reference

12 December 2020

Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets

1 reference

12 December 2020

Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease

1 reference

12 December 2020

Factors contributing to increased platelet reactivity in people with diabetes

1 reference

12 December 2020

COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment.

1 reference

12 December 2020

Aspirin: promise and resistance in the new millennium

1 reference

12 December 2020

Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease

1 reference

12 December 2020

Methods for the measurement of platelet function

1 reference

12 December 2020

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

12 December 2020

Effect of increasing doses of aspirin on platelet function as measured by PFA-100 in patients with diabetes

1 reference

12 December 2020

Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial

1 reference

12 December 2020

Screening for aspirin resistance in stable coronary artery patients by three different tests

1 reference

12 December 2020

Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions

1 reference

12 December 2020

The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study

1 reference

12 December 2020

Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis

1 reference

12 December 2020

Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial

1 reference

12 December 2020

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

12 December 2020

10.1007/S12185-010-0652-3

Identifiers

DOI

1 reference

11 November 2017

1 reference